Eton Pharmaceuticals, Inc. (ETON) Stock Grade

About Eton Pharmaceuticals, Inc.'s fundamentals

Eton Pharmaceuticals is a specialty and generic drug manufacturer with a market capitalization of $1.6 billion and a P/E ratio of 13.1, though this valuation metric reflects the company's recent losses rather than consistent profitability. The company demonstrated strong top-line momentum with revenue growth of 104.9% year-over-year, but currently operates at a net margin of -5.8%, indicating the company is not yet profitable at the bottom line. Despite accounting losses, Eton generated positive free cash flow in its latest reporting period, suggesting operational cash generation that exceeds capital expenditure requirements. The company pays no dividend and reported a net loss in its latest annual statement.